Antibody against peptide encoded by exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same

Abstract

The present invention provides a drug for preventing or treating inflammation-associated diseases in which a periostin isoform having cell adhesion activity is involved, and also provides an inhibitor of a periostin isoform having cell adhesion activity.

1 - 16 . (canceled) 
     
     
         17 . An antibody binding to one or more peptides selected from the group consisting of a peptide consisting of an amino acid sequence of SEQ ID NO: 6, a peptide consisting of an amino acid sequence of SEQ ID NO: 17 and a peptide consisting of an amino acid sequence of SEQ ID NO: 18. 
     
     
         18 . The antibody according to  claim 17 , which specifically binds to one or more peptides selected from the group consisting of a peptide consisting of an amino acid sequence of SEQ ID NO: 19, a peptide consisting of an amino acid sequence of SEQ ID NO: 20, a peptide consisting of an amino acid sequence of SEQ ID NO: 21 and a peptide consisting of an amino acid sequence of SEQ ID NO: 22. 
     
     
         19 . The antibody according to  claim 17 , which specifically recognizes a cell adhesion activity-related region of a periostin isoform having cell adhesion activity and neutralizes the cell adhesion activity of the periostin isoform. 
     
     
         20 . The antibody according to  claim 17 , which is a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody or a human antibody. 
     
     
         21 . The antibody according to  claim 20 , which is a monoclonal antibody. 
     
     
         22 . The antibody according to  claim 21 , which is produced by a hybridoma cell line designated as NITE BP-01546. 
     
     
         23 . An antibody fragment consisting of a partial fragment of the monoclonal antibody according to  claim 21 . 
     
     
         24 . An antibody derivative comprising a protein or low molecular weight drug linked to the antibody according to  claim 17 . 
     
     
         25 . An antibody derivative comprising a protein or low molecular weight drug linked to the antibody fragment according to  claim 23 . 
     
     
         26 . A hybridoma cell line designated as NITE BP-01546. 
     
     
         27 . A method for producing the antibody according to  claim 20 , the method comprising
 immunizing a non-human mammal with a peptide consisting of an amino acid sequence selected from the group consisting of an amino acid sequence of SEQ ID NO: 6, an amino acid sequence of SEQ ID NO: 17 and an amino acid sequence of SEQ ID NO: 18, or the peptide having a Cys residue added to the N-terminus,   fusing an antibody-producing cell of the animal with a myeloma cell to form a hybridoma, and   culturing the hybridoma.   
     
     
         28 . A method for detecting or quantifying a periostin isoform having cell adhesion activity in a biological sample by using the antibody according to  claim 17 . 
     
     
         29 . A method for detecting or quantifying a periostin isoform having cell adhesion activity in a biological sample by using the antibody fragment according to  claim 23 . 
     
     
         30 . A method for detecting or quantifying a periostin isoform having cell adhesion activity in a biological sample by using the antibody derivative according to  claim 24 . 
     
     
         31 . The antibody according to  claim 17 , which is produced using as an antigen a periostin Exon-21 peptide alone.